<li>artemether/lumefantrine<p>artemether/lumefantrine will increase the level or effect of fluoxetine by  affecting hepatic enzyme CYP2D6 metabolism. Contraindicated.</p></li><li>astemizole<p>fluoxetine increases levels of astemizole by decreasing metabolism. Contraindicated. Risk of QT interval prolongation.</p></li><li>cisapride<p>fluoxetine increases levels of cisapride by decreasing metabolism. Contraindicated. Risk of QT interval prolongation.</p></li><li>eliglustat<p>fluoxetine increases levels of eliglustat by affecting hepatic enzyme CYP2D6 metabolism. Contraindicated. If coadministered with strong or moderate CYP2D6 inhibitors, reduce eliglustat dose from 84 mg BID to 84 mg once daily in extensive  and intermediate metabolizers;  eliglustat is contraindiated if strong or moderate CYP2D6 inhibitors are given concomitantly with strong or moderate CYP3A inhibitors.</p></li><li>goserelin<p>goserelin increases toxicity of fluoxetine by QTc interval. Contraindicated. Increases risk of torsades de pointes.</p></li><li>isocarboxazid<p>isocarboxazid and fluoxetine both increase  serotonin levels. Contraindicated.</p></li><li>leuprolide<p>leuprolide increases toxicity of fluoxetine by QTc interval. Contraindicated. Increases risk of torsades de pointes.</p></li><li>linezolid<p>linezolid and fluoxetine both increase  serotonin levels. Contraindicated. Linezolid may increase serotonin as a result of MAO-A inhibition. If linezolid must be administered, discontinue serotonergic drug immediately and monitor for CNS toxicity. Serotonergic therapy may be resumed 24 hours after last linezolid dose or after 5 weeks of monitoring, whichever comes first.</p></li><li>lumefantrine<p>lumefantrine will increase the level or effect of fluoxetine by  affecting hepatic enzyme CYP2D6 metabolism. Contraindicated.</p></li><li>methylene blue<p>methylene blue and fluoxetine both increase  serotonin levels. Contraindicated. Methylene blue may increase serotonin as a result of MAO-A inhibition. If methylene blue must be administered, discontinue fluoxetine immediately and monitor for CNS toxicity. Fluoxetine may be resumed 24 hours after last methylene blue dose or after 5 weeks of monitoring, whichever comes first.</p></li><li>phenelzine<p>phenelzine and fluoxetine both increase  serotonin levels. Contraindicated.</p></li><li>pimozide<p>fluoxetine and pimozide both increase  QTc interval. Contraindicated.<span><br><br></span>fluoxetine increases levels of pimozide by decreasing metabolism. Contraindicated. Risk of QT interval prolongation.</p></li><li>procarbazine<p>procarbazine and fluoxetine both increase  serotonin levels. Contraindicated. Combinations is contraindicated within 5 weeks of MAOI use.</p></li><li>selegiline<p>selegiline and fluoxetine both increase  serotonin levels. Contraindicated. At least 5 weeks should elapse between discontinuation of fluoxetine and initiation of selegiline.</p></li><li>thioridazine<p>thioridazine will increase the level or effect of fluoxetine by  affecting hepatic enzyme CYP2D6 metabolism. Contraindicated.<span><br><br></span>thioridazine and fluoxetine both increase  QTc interval. Contraindicated.<span><br><br></span>fluoxetine increases levels of thioridazine by decreasing metabolism. Contraindicated. Risk of long QT syndrome.</p></li><li>tranylcypromine<p>tranylcypromine and fluoxetine both increase  serotonin levels. Contraindicated.</p></li>